Lung Cancer
Lung cancer is the most common primary malignant tumor of the lungs, and currently has the second highest number of incidence and second highest number of deaths worldwide each year. According to the data on the global cancer burden in 2020 released by the International Agency for Research on Cancer (IARC) of the World Health Organization, there will be 2.2 million new lung cancer cases worldwide in 2020 (second only to breast cancer) and 1.8 million new lung cancer deaths (far more than other cancers). Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases, and its 5-year survival rate is only about 20%.
In recent years, lung cancer drug development has progressed rapidly, and the number of marketed biologics in the world now reaches 102, focusing on targeted drugs for EGFR, ALK and other targets, and PD-1/PD-L1 immunotherapy and antibody-coupled drugs (ADCs).
- In terms of targeted therapies, drugs targeting specific gene mutations such as EGFR, ALK, ROS1, etc. have been emerging. For example, multiple generations of TKIs (tyrosine kinase inhibitors) have been developed for EGFR-mutated NSCLC, such as first-generation gefitinib, second-generation afatinib, and third-generation osimertinib. In addition, amivantamab in combination with chemotherapy has shown significant efficacy in NSCLC patients with EGFR exon 20 insertion mutation.
- For immunotherapy, PD-1/PD-L1 inhibitors such as pembrolizumab and nivolumab have made significant progress in lung cancer treatment. For example, the PAPILLON study showed that amivantamab in combination with chemotherapy significantly prolonged the median PFS in advanced NSCLC harboring EGFR exon 20 insertion mutations.6 In addition, immunotherapy has become a new standard of care option for NSCLC patients with high levels of PD-L1 expression.
- Antibody-drug conjugates (ADCs) have been an emerging research direction in lung cancer treatment in recent years.ADC drugs improve the targeting and efficacy of treatment by combining antibodies with chemotherapeutic agents or radioactive substances. For example, novel ADC drugs such as trastuzumab deruxtecan (T-DXd) have shown better efficacy in non-small cell lung cancer with HER2 mutation.
Lung Cancer Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody(CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized CD152 at 2 μg/ml can bind Anti-CD152 rabbit monoclonal antibody (CSB-RA213310A0HU), the EC50 of human CD152 protein is 27.14-34.82 ng/ml
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
Measured by its binding ability in a functional ELISA. Immobilized MET at 2 μg/ml can bind Anti-MET recombinant antibody, the EC50 is 2.379-3.094.
FACS assay shows that Human TIGIT can bind to 293F cell overexpressing human CD155.
Measured by its binding ability in a functional ELISA. Immobilized TNFSF9 at 2 μg/ml can bind TNFRSF9（CSB-MP023984HU1）, the EC50 is 2.671-3.702 ng/mL.
